EGFR and non-small cell lung carcinoma: In the phase 3 FLAURA trial, osimertinib significantly improved PFS compared with standard EGFR-TKIs gefitinib and erlotinib as first-line treatment of EGFR mutated advanced NSCLC, with a similar safety profile and lower rate of serious adverse events [64].